RxDoctor Payments DataLook up a doctor →

Alison Huggins, NP

Family · Cheraw, SCNPI 1104918499

Payments from drug & device makers

$9,913in general payments, 2019–2025

Across 611 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$910
  • Lilly USA, LLC$701
  • Pfizer$650
  • AstraZeneca$581
  • Merck$538
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$9,913100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,913 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$154,906
Medicare patients
415
Services billed
4,396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin226$185,779
TrulicityDulaglutide85$107,495
FarxigaDapagliflozin Propanediol135$107,176
MounjaroTirzepatide69$90,386
LinzessLinaclotide113$80,185
OzempicSemaglutide58$64,010
EliquisApixaban66$59,025
VraylarCariprazine Hcl22$40,829
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$35,630
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$34,094
Humulin R U-500 KwikpenInsulin Regular, Human12$25,363
MyrbetriqMirabegron38$24,554
ProliaDenosumab12$21,148
Humalog Kwikpen U-200Insulin Lispro12$19,203
JanuviaSitagliptin Phosphate27$18,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$701$197,881154 claims
Boehringer IngelheimJardiance, Spiriva Respimat$269$192,131238 claims
AstraZenecaFarxiga, Symbicort$581$122,940193 claims
AbbVieLinzess, Vraylar$1,966$121,015135 claims
Novo NordiskOzempic, Rybelsus$910$81,76773 claims
PfizerEliquis$650$59,02566 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$195$54,95570 claims
Astellas Pharma US IncMyrbetriq$20$24,55438 claims
AmgenProlia$192$21,14812 claims
MerckJanuvia$538$18,21727 claims
Johnson & JohnsonXarelto$208$16,06915 claims
NovartisEntresto$326$12,61818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Cheraw

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →